Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cleveland Biosensors was an Australian biotechnology company that specialized in the development of portable, handheld diagnostic instruments for point-of-care testing. A spin-off from the Australian Institute of Marine Science (AIMS) and James Cook University, the company commercialized the BioFiniti platform, which utilized microfluidic technology to detect marine toxins, pathogens, and chemical residues in real-time. The company's primary focus was on food safety and environmental monitoring, specifically targeting the detection of paralytic shellfish toxins in seafood to prevent foodborne illness. Despite receiving venture capital backing and launching its lead product, the company ceased operations and was deregistered in 2011.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cleveland Biosensors.